文献速递血液净化与透析

抑制核心岩藻糖基化减轻大鼠葡萄糖诱导的腹膜纤维化

Inhibiting core fucosylation attenuates glucose-induced peritoneal fibrosis in rats.
PubMed 文献 · Kidney Int · 2018-03-20

长期腹膜透析高糖透析液暴露可致腹膜纤维化及超滤失败,目前缺乏有效治疗。该研究在大鼠模型中证实核心岩藻糖基化在腹膜纤维化时富集,阻断核心岩藻糖基化可同时抑制TGF-β1与PDGF信号通路并显著减轻腹膜纤维化,效果优于单用伊马替尼。

要点

  • 核心岩藻糖基化在高糖透析液诱导的腹膜纤维化大鼠腹膜中富集。
  • 阻断核心岩藻糖基化可同时抑制TGF-β1和PDGF通路,减轻腹膜纤维化。
  • 阻断核心岩藻糖基化对腹膜纤维化的抑制效果优于单用伊马替尼。

核心结论

  • 核心岩藻糖基化通过调控多条信号通路激活而促进腹膜纤维化发展,可能是治疗腹膜纤维化的潜在新靶点。

研究设计与样本

  • 研究采用高糖透析液诱导的腹膜纤维化大鼠模型,比较阻断核心岩藻糖基化与伊马替尼对腹膜纤维化的作用。

主要发现

  • 高糖透析液诱导的腹膜纤维化大鼠腹膜中核心岩藻糖基化富集。
  • 阻断核心岩藻糖基化可同时灭活TGF-β1和PDGF信号通路,显著减轻大鼠腹膜纤维化。
  • 阻断核心岩藻糖基化对腹膜纤维化的抑制效果优于单用伊马替尼。

临床怎么用

  • 核心岩藻糖基化可能作为未来药物开发靶点,用于治疗腹膜透析相关腹膜纤维化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ultrafiltration failure is a major complication of long-term peritoneal dialysis, resulting in dialysis failure. Peritoneal fibrosis induced by continuous exposure to high glucose dialysate is the major contributor of ultrafiltration failure, for which there is no effective treatment. Overactivation of several signaling pathways, including transforming growth factor-β1 (TGF-β1) and platelet-derived growth factor (PDGF) pathways, contribute to the development of peritoneal fibrosis. Therefore, simultaneously blocking multiple signaling pathways might be a potential novel method of treating peritoneal fibrosis. Previously, we showed that core fucosylation, an important posttranslational modification of the TGF-β1 receptors, can regulate the activation of TGF-β1 signaling in renal interstitial fibrosis. However, it remains unclear whether core fucosylation affects the progression of peritoneal fibrosis. Herein, we show that core fucosylation was enriched in the peritoneal membrane of rats accompanied by peritoneal fibrosis induced by a high glucose dialysate. Blocking core fucosylation dramatically attenuated peritoneal fibrosis in the rat model achieved by simultaneously inactivating the TGF-β1 and PDGF signaling pathways. Next the protective effects of blocking core fucosylation and imatinib (a selective PDGF receptor inhibitor) on peritoneal fibrosis were compared and found to exhibit a greater inhibitory effect over imatinib alone, suggesting that blocking activation of multiple signaling pathways may have superior inhibitory effects on the development of peritoneal fibrosis. Thus, core fucosylation is essential for the development of peritoneal fibrosis by regulating the activation of multiple signaling pathways. This may be a potential novel target for drug development to treat peritoneal fibrosis.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Li L, Shen N, Wang N, et al. Inhibiting core fucosylation attenuates glucose-induced peritoneal fibrosis in rats. Kidney Int. 2018. PMID: 29571940. doi:10.1016/j.kint.2017.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。